SEC Form 4 · accession 0001643071-26-000007
Immunovant, Inc. · IMVT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atul Pande
Director
Period of report
Jul 24, 2026
Accepted (ET)
Jul 24, 2026 · 5:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001764013
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 24, 2026 | M | 1,500 | $8.43 | A | 118,231 | D | |
| Common Stock | Jul 24, 2026 | S | 1,500 | $39.80 | D | 116,731 | D | |
| Common Stock | holding | — | — | — | 20,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $8.43 | Jul 24, 2026 | M | 1,500 | D | — | Nov 19, 2029 | Common Stock | 1,500 | 66,681 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
- F2Reflects an award of stock options to purchase Common Shares that is fully vested.